Although immunotherapy is increasingly employed in breast cancer, PD-L1 expression is the most widely used biomarker associated with tumor immune checkpoint treatment; yet, for the majority of tumors, PD-L1 measured by IHC assays are unsatisfactory as a biological marker for the anti-PD-1/PD-L1 therapy [41]. This evidence concerns the gene CD274 and breast carcinoma.